Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02774291 · ClinicalTrials.gov registry record · Early Phase 1
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
A Early Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT02774291 is a Early Phase 1 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 3 participants.
The verdict
NCT02774291, a Early Phase 1 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects of anti-ESO (cancer/test antigen) murine T-cell receptor (mTCR)-transduced autologous peripheral blood lymphocytes and combination chemotherapy with cyclophosphamide and fludarabine phosphate in treating patients with cancer that has spread to other places in the body (metastatic) and expresses the gene NY-ESO-1. Donor white blood cells that are treated in the laboratory with anti-cluster of differentiation (CD)3 may help treat metastatic cancer. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Aldesleukin may stimulate white blood cells, including natural killer cells, to kill metastatic cancer cells. Giving anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes together with combination chemotherapy and aldesleukin may kill more cancer cells.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL Filgrastim
- DRUG Fludarabine Phosphate
- BIOLOGICAL Aldesleukin
- BIOLOGICAL Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2020-08-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02774291
The ClinicalTrials.gov registry entry for NCT02774291 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02774291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02774291 about?
NCT02774291 is a clinical study titled "Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes". This pilot clinical trial studies the side effects of anti-ESO (cancer/test antigen) murine T-cell receptor (mTCR)-transduced autologous peripheral blood lymphocytes and combination chemotherapy with cyclophosphamide and fludarabine phosphate in treating patients with cancer that has spread to other...
What is the current status of trial NCT02774291?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2017-04-20. Estimated completion is 2020-08-04.
What interventions are being tested in trial NCT02774291?
The interventions under investigation include: Cyclophosphamide (DRUG), Filgrastim (BIOLOGICAL), Fludarabine Phosphate (DRUG), Aldesleukin (BIOLOGICAL), Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02774291?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.